Overview
- A peer‑reviewed multicentre validation published in the journal Biomarker Research shows the qMIDS‑V3 brush test detected oral squamous cell carcinoma with AUC 0.975, sensitivity 95.7%, specificity 95.1%, and 95.5% overall accuracy.
- The study tested 1,090 paired brush biopsies from 545 patients and used qPCR measurement of four genes (INHBA, S100A16, YAP1, POLR2A) to compute a malignancy index per sample.
- Because the test uses a non‑invasive oral brush and gives results in about one hour, researchers say it could reduce unnecessary scalpel biopsies for low‑risk lesions and enable repeated surveillance of at‑risk patients.
- The lead author disclosed patents held by QM Innovation Ltd that cover the qMIDS method and the team says it is seeking commercial partners with a conditional estimate that clinical availability could follow in roughly two years if development and regulatory steps progress.
- Wider adoption will require external and regulatory validation, manufacturing and cost plans, and real‑world studies to confirm performance across settings and to measure whether the test shortens diagnostic delays and improves early detection for patients.